Back to Search
Start Over
The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism
- Source :
- Nefrología (English Edition), Vol 36, Iss 1, Pp 10-18 (2016)
- Publication Year :
- 2016
- Publisher :
- Elsevier, 2016.
-
Abstract
- Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.
Details
- Language :
- English
- ISSN :
- 20132514
- Volume :
- 36
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nefrología (English Edition)
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.b9842c9135455992553eff5ace1d7f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.nefroe.2016.02.006